Tislelizumab vs sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 study

by Richard S. Finn, Masatoshi Kudo, Gisoo Barnes, Tim Meyer, Frederic Boisserie, Ramil Abdrashitov, Yaxi Chen, Songzi Li, Andrew X. Zhu, Shukui Qin, Arndt Vogel
Published 2024-02-01